MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease - PubMed (original) (raw)
. 2006 Aug 18;281(33):23658-67.
doi: 10.1074/jbc.M513646200. Epub 2006 Jun 14.
Affiliations
- PMID: 16774924
- DOI: 10.1074/jbc.M513646200
Free article
MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease
Ainsley A Culbert et al. J Biol Chem. 2006.
Free article
Abstract
MAPK-activated protein kinase 2 (MAPKAP K2 or MK2) is one of several kinases directly regulated by p38 MAPK. A role for p38 MAPK in the pathology of Alzheimer disease (AD) has previously been suggested. Here, we provide evidence to suggest that MK2 also plays a role in neuroinflammatory and neurodegenerative pathology of relevance to AD. MK2 activation and expression were increased in lipopolysaccharide (LPS) + interferon gamma-stimulated microglial cells, implicating a role for MK2 in eliciting a pro-inflammatory response. Microglia cultured ex vivo from MK2-deficient (MK2-/-) mice demonstrated significant inhibition in release of tumor necrosis factor alpha, KC (mouse chemokine with highest sequence identity to human GROs and interleukin-8), and macrophage inflammatory protein 1alpha on stimulation with LPS + interferon gamma or amyloid-beta peptide (1-42) compared with MK2+/+ wild-type microglia. Consistent with an inhibition in pro-inflammatory mediator release, cortical neurons co-cultured with LPS + interferon gamma-stimulated or amyloid-beta peptide (1-42)-stimulated MK2-/- microglia were protected from microglial-mediated neuronal cell toxicity. In a transgenic mouse model of AD in which amyloid precursor protein and presenilin-1 harboring familial AD mutations are overexpressed in specific regions of the brain, elevated activation and expression of MK2 correlated with beta-amyloid deposition, microglial activation, and up-regulation of tumor necrosis factor alpha, macrophage inflammatory protein 1alpha, and KC gene expression in the same brain regions. Our data propose a role for MK2 in AD brain pathology, for which neuroinflammation involving cytokines and chemokines and overt neuronal loss have been documented.
Similar articles
- Intranasal MMI-0100 Attenuates Aβ1-42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway.
Jiang J, Wang Z, Liang X, Nie Y, Chang X, Xue H, Li S, Min C. Jiang J, et al. Front Immunol. 2019 Nov 26;10:2707. doi: 10.3389/fimmu.2019.02707. eCollection 2019. Front Immunol. 2019. PMID: 31849936 Free PMC article. - MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation--relevance in a mouse model of Parkinson's disease.
Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. Thomas T, et al. J Neurochem. 2008 Jun;105(5):2039-52. doi: 10.1111/j.1471-4159.2008.05310.x. Epub 2008 Feb 22. J Neurochem. 2008. PMID: 18298661 - CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.
Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M. Tan J, et al. J Neurosci. 2000 Oct 15;20(20):7587-94. doi: 10.1523/JNEUROSCI.20-20-07587.2000. J Neurosci. 2000. PMID: 11027218 Free PMC article. - Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ, Muñetón-Gómez V, Alvárez MI, Toledano-Díaz A. Merino JJ, et al. Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review. - Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease.
Kaur D, Sharma V, Deshmukh R. Kaur D, et al. Inflammopharmacology. 2019 Aug;27(4):663-677. doi: 10.1007/s10787-019-00580-x. Epub 2019 Mar 14. Inflammopharmacology. 2019. PMID: 30874945 Review.
Cited by
- Applications of high content screening in life science research.
Zock JM. Zock JM. Comb Chem High Throughput Screen. 2009 Nov;12(9):870-76. doi: 10.2174/138620709789383277. Comb Chem High Throughput Screen. 2009. PMID: 19938341 Free PMC article. Review. - The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a Discovery Target in Stroke.
Sun J, Nan G. Sun J, et al. J Mol Neurosci. 2016 May;59(1):90-8. doi: 10.1007/s12031-016-0717-8. Epub 2016 Feb 3. J Mol Neurosci. 2016. PMID: 26842916 Review. - The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease.
Corrêa SA, Eales KL. Corrêa SA, et al. J Signal Transduct. 2012;2012:649079. doi: 10.1155/2012/649079. Epub 2012 Jun 25. J Signal Transduct. 2012. PMID: 22792454 Free PMC article. - MAPK usage in periodontal disease progression.
Li Q, Valerio MS, Kirkwood KL. Li Q, et al. J Signal Transduct. 2012;2012:308943. doi: 10.1155/2012/308943. Epub 2012 Jan 23. J Signal Transduct. 2012. PMID: 22315682 Free PMC article. - In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice.
Gerits N, Kostenko S, Moens U. Gerits N, et al. Transgenic Res. 2007 Jun;16(3):281-314. doi: 10.1007/s11248-006-9052-0. Epub 2007 Jan 12. Transgenic Res. 2007. PMID: 17219248 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases